Bernard Coulie - Mar 29, 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
President and CEO, Director
Signature
/s/ Mike Ouimette, attorney-in-fact
Stock symbol
PLRX
Transactions as of
Mar 29, 2023
Transactions value $
$0
Form type
4
Date filed
3/31/2023, 05:54 PM
Previous filing
Feb 6, 2023
Next filing
Apr 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Award $0 +68.7K +28.49% $0.00 310K Mar 29, 2023 Direct F1, F2
holding PLRX Common Stock 409K Mar 29, 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 68,749 shares.
F2 Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.
F3 Shares are held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.